Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,699
datasets available to search
ShareScore release 0.9.0
Dataset results
6,699 results for “DEPRESSION”
Possible sarcopenia and depression
<p><span>We enrolled a total of 10,058 participants for baseline characterization from the 17,708 respondents </span><span>at </span><span>the baseline survey in 2011. Exclusions were based on the following criteria: those with no information about age (n=3</span><span>70</span><span>), missing height or weight measures (n=1,558), missing data on PS (n=4,302), and missing data on at least one entry in the CES-D.10 scale (n=1,420). For the cohort analysis, we further excluded respondents with depression at baseline (n=3,887) and those with missing CES-D.10 scores during the follow-up period (n=445)</span><span>.</span> <span>A</span> <span>total of 5,726 subjects included for cohort analysis</span></p>
Role of citicoline and choline in the treatment of post-stroke depression: an exploratory study
<p><strong>Objective: </strong>To compare selective serotonin reuptake inhibitors (SSRIs) and nootropic drugs in the reduction of anxiety and depressive symptoms in post-stroke patients.</p> <p><strong>Methods: </strong>This retrospective cohort study included patients diagnosed with post-stroke depression that were treated with either SSRIs or nootropic drugs (i.e. citicoline or choline alphoscerate). Depression and anxiety were assessed using the Hamilton Rating Scales. Statistical associations between the use of nootropic drugs and mood disorder improvements were determined by measuring assessment scores at 6-months.</p> <p><strong>Results: </strong>A total of 44 post-stroke patients with depression (aged 45-75 years) were enrolled in the study: 20 were treated with SSRIs and 24 received nootropic drugs. From baseline to follow-up, the SSRI group showed a large effect size with regard depression (success rate difference [SRD] 0.57; 95% confidence interval [CI] 0.21, 0.79) and anxiety (SRD 0.49; 95% CI 0.14, 0.74), whereas the nootropic group showed a small effect size for depression (SRD 0.16; 95% CI -0.17, 0.46) and a small effect size for anxiety (SRD 0.36; 95% CI -0.03, 0.62).</p> <p><strong>Conclusion: </strong>The administration of nootropic drugs could be a valid therapeutic strategy to manage post-stroke patients suffering from mild-moderate anxiety or anxious-depressive syndrome, but this requires further research.</p>
Multimodal Depression Dataset
<h1>描述</h1> <p>多模态抑郁数据集(Multimodal Depression Dataset)由中国科学院大学和中国科学院心理研究所计算网络心理学实验室收集。</p> <p>该数据集包含来自254名参与者的视频、音频、脑电图(EEG)和步态(Gait)数据。</p> <h2> </h2>
Data from: The influence of depression on cognitive control: disambiguating approach and avoidance tendencies
Dysfunctions of approach and avoidance motivation play an important role in depression, which in turn may affect cognitive control, i.e., the ability to regulate thoughts and action to achieve internal goals. We use a novel experimental paradigm, i.e. a computer simulated driving-task, to study the impact of depression on cognitive control by measuring approach and avoidance actions in continuous time. In this task, 39 subjects with minimal to severe depression symptoms were instructed to use a joystick to move a virtual car as quickly as possible to a target point without crossing a stop-sign or crashing into a wall. We recorded their continuous actions on a joystick and found that depression 1) leads to further stopping distance to task target; and 2) increases the magnitude of late deceleration (avoidance) but not early acceleration (approach), which was only observed in the stop-sign condition. Taken together, these results are consistent with the hypothesis that depressed individuals have greater avoidance motivation near stopping target, but are minimally affected by approach motivation.
The effect of intravenous thrombolytic therapy on post stroke depression and cognitive dysfunction: A 3-months follow up study
<p>Several studies have demonstrated the efficacy of intravenous thrombolytic therapy with recombinant plasminogen activator (rt-PA) on functional recovery at 3-18 months following the treatment. The objectives of this study were to investigate differences between thrombolytic or no thrombolytic treatment and if could be a relationship between patients who have underwent the thrombolytic treatment in terms of depressive symptoms and cognitive impairment. In this retrospective study, we evaluated 92 patients affected by ischemic stroke recruited from our rehabilitation center, coming from a Stroke Unit. All the eligible subjects were assessed at admission (T0) and two months later, at discharge, upon concluded the rehabilitation program (T1). The patients were divided into two groups: Thrombolysis Group (n.40 subjects) and no Thrombolysis Group (n.52 subjects). Cognitive functions were evaluated with the Montreal Overall Cognitive Assessment. Functional status were evaluated with the Barthel Index and the Functional Independent Misure. We administered Beck Depression Inventory-II to verify the presence of a depressive state. We found that at three months after stroke, the prevalence of depressive symptoms and cognitive improvement, among patient who had undergone thrombolytic treatment, and who had not, was not different. Conversely, we found an improvement of depressive symptoms in each group.</p>
Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment
<p>Anxiety and depression in Parkinson’s disease (PD) reduce well-being of the patients. Emotional alterations influence motor skills and cognitive performance; moreover, they contribute significantly and independently to worsen rehabilitative treatment response. We investigated anxiety, depression, and quality of life in PD patients subjected to multidisciplinary rehabilitative training. The self-controlled study included 100 PD patients (49 males and 51 females with the mean age of 64.66 years) admitted to 60 days hospitalization rehabilitative program, between January 2017 and December 2018. Motor, cognitive, linguistic abilities, and functional independence were evaluated at admission (T0 baseline visit) and 60 days after (T1) the multidisciplinary rehabilitation including motor exercises, speech therapies, and cognitive intervention. The multidisciplinary rehabilitation improved functional status in PD patients and exerted its positive effects on mood, motor abilities, autonomy in the activities of daily life, perception of quality of life, cognitive performance and speech skills. Non-motor symptoms may worsen severe disability and reduce quality of life. They are often poorly recognized and inadequately treated. Nonetheless, multidisciplinary rehabilitative training represents an optimal strategy to improve disease management.</p>
Thai depression detection dataset and baseline models
<p>Depression detection dataset and baseline models. If you are only interested in the dataset, download data.zip.</p> <p>Please cite: Hämäläinen, M., Patpong, P., Alnajjar, K., Partanen, N. & Rueter, J. (2021) Detecting Depression in Thai Blog Posts: a Dataset and a Baseline. In <em>Proceedings of the 7th Workshop on Noisy User-generated Text (W-NUT 2021)</em>.</p>
Distributed Subnetworks of Depression Defined by Direct Intracranial Neurophysiology
<p>SuperEEG model associated with "Scangos, K.W et al. 2021. Distributed Subnetworks of Depression Defined by Direct Intracranial Neurophysiology. Front. Hum. Neurosci."</p> <p> </p> <p>Dataset includes the following files:</p> <p> FULL_MODEL.model.npy - SuperEEG model trained on the entire study cohort. File is in Python/Numpy-readable format. Each row/column corresponds to a pair of intracranial EEG electrode contacts.</p> <p> FULL_MODEL.locs.csv - Three-dimensional coordinates of intracranial EEG electrode contacts in Montreal Neurological Institute (MNI) format. File is in a comma-separated values (CSV) format.</p>
The Effect of Color Therapy on Depression, Stress, Anxiety and Quality of Life in Hemodialysis Patients: A Randomized Controlled Study
ClinicalTrials.gov study NCT06879808. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
ClinicalTrials.gov study NCT03423680. IPD Sharing: NO. Countries: 1. Publications: 0.
Using Learning Teams for Reflective Adaptation for Diabetes and Depression
ClinicalTrials.gov study NCT00414986. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Propofol Versus Remimazolam Intravenous Anesthesia on Respiratory Depression
ClinicalTrials.gov study NCT06816173. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treat
ClinicalTrials.gov study NCT05973851. IPD Sharing: YES. Countries: 6. Publications: 0.
Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic
ClinicalTrials.gov study NCT04487171. IPD Sharing: NO. Countries: 1. Publications: 0.
Combined Effect of TCC-I and BATD on Depressive Symptoms and Insomnia
ClinicalTrials.gov study NCT06633263. IPD Sharing: YES. Countries: 1. Publications: 0.
Effects of Testosterone in Women With Depression
ClinicalTrials.gov study NCT00676676. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide
ClinicalTrials.gov study NCT03666390. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
ClinicalTrials.gov study NCT04400266. IPD Sharing: NO. Countries: 1. Publications: 0.
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
ClinicalTrials.gov study NCT05220202. IPD Sharing: NO. Countries: 1. Publications: 0.
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
ClinicalTrials.gov study NCT00761306. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.